Ultragenyx Pharmaceutical Inc. has made a significant stride in the treatment of Sanfilippo syndrome Type A (MPS IIIA) with the FDA’s acceptance of its Biologics License Application (BLA) for UX111 (rebisufligene etisparvovec). This AAV9 gene therapy, if approved by the PDUFA action date of September 19, 2026, would mark the first-ever approved therapy for this rare and devastating neurodegenerative disease that primarily affects young children, leading to severe cognitive decline and early mortality.

The importance of this development extends beyond the immediate patient population. Sanfilippo syndrome Type A is characterized by a deficiency in the sulfamidase enzyme, resulting in the accumulation of heparan sulfate in the brain and subsequent neurodegeneration. The updated long-term clinical data presented at WORLDSymposium™ 2026, which includes up to eight years of follow-up, demonstrates significant clinical improvements compared to natural history data, reinforcing the therapeutic potential of UX111. The therapy’s robust safety profile and durable effects could pave the way for similar gene therapies targeting other lysosomal storage disorders, highlighting a promising trend in precision medicine for rare genetic diseases.

For professionals in the longevity and healthspan research fields, the development of UX111 underscores the growing recognition of gene therapy as a viable strategy for addressing severe, previously untreatable conditions. The successful advancement of this therapy could catalyze further investment and research into gene-based interventions, potentially transforming the landscape of treatment for neurodegenerative diseases and expanding the therapeutic arsenal available for rare genetic disorders.

Source: globenewswire.com